Simon Kohl's banner
Simon Kohl's profile picture

Simon Kohl

@saakohl • 3,096 subscribers

Founder at Latent Labs.

Videos

LIVE
1.2k

Anya Rossi

sweetdream.ai

SweetDream.aiSponsored•Livecam
Streaming Now

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

HD live stream
Exclusive private shows
1.2k viewers online

Free preview available • Premium content

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:
1:56
saakohl's profile picture

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:

Simon Kohl

121,575 views • 6 months ago

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:
2:27
saakohl's profile picture

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:

Simon Kohl

26,654 views • 2 months ago

Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot. Technical report: Blog: Apply for access: partnerships@latentlabs.com
0:35
saakohl's profile picture

Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot. Technical report: Blog: Apply for access: [email protected]

Simon Kohl

54,814 views • 9 months ago

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:
0:25
saakohl's profile picture

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:

Simon Kohl

57,495 views • 1 year ago

No more content to load